# The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

> **NCT01860482** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 39 (actual)

## Conditions studied

- Reflux Esophagitis

## Interventions

- **DRUG:** Newrabell® Tablet 10mg

## Key facts

- **NCT ID:** NCT01860482
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2015-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01860482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01860482, "The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01860482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*